BSG 005
Alternative Names: BSG 005G; BSG-005Latest Information Update: 28 Jul 2025
At a glance
- Originator Greenlight Clinical; Norwegian university of science and technology; Nucleus Network; Select Pharma; SINTEF Materials and Chemistry
- Developer Biosergen; Greenlight Clinical; Nucleus Network; Select Pharma
- Class Antifungals; Macrolides; Polyenes
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Mycoses
Highest Development Phases
- Phase I/II Mycoses
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Mycoses in Norway (IV, Infusion)
- 28 Jul 2025 No recent reports of development identified for research development in Mycoses in Norway
- 28 Jul 2025 No recent reports of development identified for research development in Mycoses in Norway (PO)